Business
Tyra Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
-Initiated patient dosing with TYRA-300 in SURF301 oncology study- -Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for
About this update from Tyra Biosciences, Inc.
[{"type":"text","content":"-Initiated patient dosing with TYRA-300 in SURF301 oncology study-\n-Expanded pipeline beyond oncology into genetically defined conditions with TYRA-300 for achondroplasia-\n-Cleared IND for TYRA-200 Phase 1 study; first patient dosed expected in 2H 2023 -\n-Well-capitalized with cash and cash equivalents of $251.2 million as of YE 2022-\nCARLSBAD, Calif., March 22, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the quarter and year ended December 31, 2022, and highlighted recent corporate progress.\n\"2022 was a momentous year for TYRA – we achieved significant milestones, evolved into a clinical-stage company, and leveraged our expertise in FGFR biology to expand our therapeutic focus beyond oncology to include genetically defined conditions,\" said Todd Harris, CEO of TYRA. \"We believe TYRA-300 has the potential to become a best-in-class agent and we look forward to advancing it in both oncology and achondroplasia. Further, we have made steady progress utilizing our SNÅP discovery engine and expect to nominate additional clinical candidates.\"\nAlan Fuhrman, CFO of TYRA, added, \"TYRA is in a very strong financial position to begin 2023, with $251.2 million in cash and cash equivalents at year-end 2022, representing more than two years of expected cash runway to support our current development plans across our precision medicine platform.\"\nFourth Quarter 2022 and Recent Corporate Highlights\nTYRA-300\nInitiated SURF301 Phase 1/2 Study for Oncology. In November 2022, TYRA announced that patient dosing had commenced in its Phase 1/2 SURF301 clinical study of TYRA-300. SURF301 (NCT05544552) was designed to determine the optimal and maximum tolerated doses (MTD) and the recommended Phase 2 dose (RP2D) of TYRA-300, as well as to evaluate the preliminary antitumor activity of TYRA-300.Expanded Development into Achondroplasia. In March 2023, TYRA announced the expansion of development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results in a study performed in collaboration with the Imagine Institute in Paris, France. TYRA-300, an investigational agent, is a once-daily oral FGFR3...